Drug Monograph

Drug/Drug Class:	**Diclegis™ (doxylamine succinate and pyridoxine hydrochloride) delayed release tablet/ antihistamine/B_6 analog**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Diclegis™ is available as a delayed-release tablet containing 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride.
Manufacturer:	Duchesnay USA, Inc., Bryn Mawr, PA, 19010,
Indications:	Diclegis™ is a fixed dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a Vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Costs:	$4.75 per delayed release tablet of Diclegis™ WholesaleAcquisitionCost
Summary of Findings:	MO HealthNet Division recommends Prior Authorization status for this product.
Status Recommendation:	☒ Prior Authorization (PA) Required ☐ Clinical Edit ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Katie Wilbers, PharmD
Date: June 6, 2014